Dr. Jost Reinhard appointed new head of Investor Relations at Bayer

Leverkusen, September 19, 2023 – Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States. Reinhard will report directly to CEO Bill Anderson in his new capacity. He succeeds Oliver Maier (57), who has headed up the Investor Relations department since March 2017 and as of October 1 will continue to work for Bayer in a senior advisory role.

Jost Reinhard was born in Traben-Trarbach, Germany, on April 28, 1972. He studied pharmacy in Bonn, Germany, and Dijon, France, and earned his doctorate in molecular toxicology and medicinal chemistry from the German Cancer Research Center in Heidelberg. Reinhard began his career at the company in 2001, in the Research & Development department of the Berlin-based company Schering AG, which was acquired by Bayer in 2006. After working in a variety of positions in areas such as Investor Relations and Corporate Communications, from 2010 onward Reinhard was appointed to commercial leadership roles with increasing responsibility in Australia, Poland and France. In 2021, he relocated to the United States to head the Cell and Gene Therapy unit, a key area of innovation for Bayer.

Jost Reinhard is married and has three children.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Follow us on Twitter https://twitter.com/bayer

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.